I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists.
Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Nuclear Medicine Imaging of Elbow and Forearm Injuries
Published in: Nuclear medicine and radiological imaging in sports injuries
Imaging the Functional Brain-Heart Axis: Mental Stress and Cardiac Dysfunction.
Published in: Autonomic Innervation of the Heart.
Imaging of the autonomic nervous system in cardiac amyloidosis
Nuclear medicine imaging techniques
Published in: Nuclear Medicine and Radiologic Imaging in Sports Injuries
Nuclear medicine is a rapidly developing field which focuses on the imaging of physiological processes and the evaluation of treatment of specific diseases. It involves the use of radiopharmaceuticals for both purposes. Different radiopharmaceuticals have different kinetics and can therefore be used to image processes in the body, the function of an organ or the presence of a specific cellular target. In sports medicine, bone scintigraphy and leukocyte scintigraphy play important roles. Radiopharmaceuticals in bone scintigraphy are diphosphonate complexes which are absorbed onto the hydroxyapatite crystal of newly...
Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer
Published in: Cancer Discovery
It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer. We performed a feasibility study to assess ER availability before and during fulvestrant. Sixteen patients with ER-positive metastatic breast cancer underwent positron emission tomography/computed tomography (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18 F] fluoroestradiol (FES) uptake. Incomplete reduction in ER availability was predefined as = 1.5. In total, 131 FES-positive lesions...
